)
Edge23 Jan 2026
Death, Taxes, and Garbage: The Story of WM
How Waste Management turned garbage into one of America's most stable business models through landfills, regulation, and nationwide scale.
Viridian Therapeutics
Viridian Therapeutics (VRDN) investor relations material
Viridian Therapeutics Corporate Presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Corporate Presentation summary6 Jan, 2026
Strategic vision and market focus
Aims to lead in autoimmune diseases, starting with thyroid eye disease (TED), addressing unmet needs and expanding patient access.
Building a diversified TED portfolio with veligrotug (IV), elegrobart (SC), and a TSHR inhibitor, with plans for pipeline expansion into other autoimmune indications.
TED market is valued at ~$2B annually, with low penetration and high demand for new, convenient therapies.
Launch preparations include experienced leadership, strong KOL relationships, and a focused sales strategy targeting ~2,000 core prescribers.
Clinical development and trial results
Veligrotug demonstrated robust efficacy in two phase 3 trials (THRIVE, THRIVE-2), meeting all primary and secondary endpoints in both active and chronic TED.
Achieved rapid onset of effect, significant proptosis and diplopia improvements, and strong durability, with 70% of responders maintaining benefit at 52 weeks.
Veligrotug was generally well-tolerated, with low rates of hearing impairment and no treatment-related serious adverse events.
Elegrobart, a subcutaneous anti-IGF-1R, shares the same binding domain as veligrotug and is being evaluated in phase 3 REVEAL trials for both active and chronic TED, with topline data expected in Q1 and Q2 2026.
Phase 1 data for elegrobart showed extended half-life, sustained IGF-1 levels, and a favorable safety profile.
Pipeline and future catalysts
Veligrotug has a PDUFA target date of June 30, 2026, with potential for rapid commercial adoption if approved.
Elegrobart is the only remaining autoinjector SC product in phase 3 for TED, offering transformative convenience and potential market expansion.
TSHR inhibitor IND submission anticipated in Q4 2026, targeting TED and Graves’ disease.
FcRn inhibitor portfolio (VRDN-006, VRDN-008) targets broader autoimmune markets, with VRDN-008 showing deeper and more sustained IgG reduction and longer half-life in NHP studies compared to efgartigimod.
FcRn market for MG and CIDP projected to exceed $11B by 2030, with Viridian’s portfolio positioned to capture significant share.
Veligrotug's strategy for new-start TED patients?
Elegrobart's plan to expand the TED market?
VRDN-008's competitive edge in FcRn market?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Viridian Therapeutics earnings date
Q4 202527 Feb, 2026
Viridian Therapeutics
Next Viridian Therapeutics earnings date
Q4 202527 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Viridian Therapeutics Inc. is a biotechnology company focused on developing treatments for patients with serious diseases, particularly those related to rare and underserved conditions. The company’s primary area of research includes therapies for thyroid eye disease (TED) and other autoimmune and inflammatory diseases. Viridian Therapeutics employs innovative biologics and small-molecule technologies to address unmet medical needs and improve patient outcomes through targeted therapeutic approaches. The company is headquartered in Waltham, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage